Sachiko Kadowaki

Sachiko Kadowaki

Auto-generated profile, based on publicly available information

Sachiko Kadowaki

The Hospital for Sick Children

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2023 in Journal of the American Heart Association
Verified
Journal Article
Closed access
SKSachiko Kadowaki
Sachiko Kadowaki
MSM. Ahsan Siraj
M. Ahsan Siraj
WCWeiden Chen
Weiden Chen
JWJian Wang
Jian Wang
MPMarlee Parker
Marlee Parker
OHOsami Honjo
Osami Honjo
Background: Heart transplantation with a donation after circulatory death (DCD) heart is complicated by substantial organ ischemia and ischemia–reperfusion injury. Exenatide, a glucagon‐like peptide−1 receptor agonist, manifests protection against cardiac ischemia–reperfusion injury in other settings. Here we evaluate the effects of exenatide on DCD hearts in juvenile pigs. Methods and Results: DCD hearts with 15‐minutes of global warm ischemia after circulatory arrest were reperfused ex vivo and switched to working mode. Treatment with concentration 5‐nmol exenatide was given during reperfusion. DCD hearts treated with exenatide showed higher myocardial oxygen consumption (exenatide [n=7] versus controls [n=7], over 60–120 minutes of reperfusion, P <0.001) and lower cardiac troponin‐I release (27.94±11.17 versus 42.25±11.80 mmol/L, P =0.04) during reperfusion compared with controls. In working mode, exenatide‐treated hearts showed better diastolic function (dp/dt min: −3644±620 versus −2193±610 mm Hg/s, P <0.001; Tau: 15.62±1.78 versus 24.59±7.35 milliseconds, P =0.02; lateral e ′ velocity: 11.27 ± 1.46 versus 7.19±2.96, P =0.01), as well as lower venous lactate levels (3.17±0.75 versus 5.17±1.44 mmol/L, P =0.01) compared with controls. Higher levels of activated endothelial nitric oxide synthase (phosphorylated to total endothelial nitric oxide synthase levels: 2.71±1.16 versus 1.37±0.35, P =0.02) with less histological evidence of endothelial damage (von Willebrand factor expression: 0.024±0.007 versus 0.331±0.302, pixel/μm, P =0.04) was also observed with exenatide treatment versus controls. Conclusions: Acute treatment of DCD hearts with exenatide limits myocardial and endothelial injury and improves donor cardiac function.

1 October 2020 in Artificial Organs
Verified
Journal Article
Closed access
PDF file
YKYasuyuki Kobayashi
Yasuyuki Kobayashi
YKYasuhiro Kotani
Yasuhiro Kotani
NSNaoya Sakoda
Naoya Sakoda
SKSachiko Kadowaki
Sachiko Kadowaki
SKShingo Kasahara
Shingo Kasahara

6 May 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
SKSachiko Kadowaki
Sachiko Kadowaki
MVMaelys Venet
Maelys Venet
TTTeerapong Tocharoenchok
Teerapong Tocharoenchok
KYKok Hooi Yap
Kok Hooi Yap
CFChun‐Po Steve Fan
Chun‐Po Steve Fan
OHOsami Honjo
Osami Honjo
Background: This study aimed to assess impact of atrioventricular valve (AVV) regurgitation onset, timing of AVV repair (AVVr), ventricular morphology, and era effect on AVVr outcomes in a single ventricle population. Methods: A retrospective review of 155 patients with single ventricle physiology who underwent AVVr between 1998 and 2022 was conducted. Transplant‐free survival, discharge alive, and AVV reoperation were assessed using the Kaplan–Meier survival method, stratified by the timing of AVVr (Group1 [G1], prebidirectional cavopulmonary shunt, N=33; G2, at or post‐shunt, N=93; G3, at or post‐Fontan, N=29). Cox proportional hazard models were used to assess the association of the timing of AVVr with death or transplant. Results: Transplant‐free survival at 10 years was lowest in G1 (G1, 16% [95% CI, 4%–35%]; G2, 65% [95% CI, 53%–74%]; G3, 85% [95% CI, 65%–94%], P <0.001). In the multivariate analysis, AVVr prebidirectional cavopulmonary shunt was an independent risk factor for failure to be discharged alive ( P <0.001) but not for overall survival ( P =0.12). Meanwhile, the likelihood of discharge alive improved over the period in the entire cohort ( P <0.001), and right ventricle morphology ( P =0.02) and weight <5 kg ( P <0.01) at AVVr were significantly associated with death. In the multistate model, persistent or recurrent AVV regurgitation and ventricular dysfunction post‐sAVVr were significantly associated with death, with hazard ratios of 3.8 (95% CI, 2.0–7.3, P <0.001) and 32 (95% CI, 13–77, P <0.001), respectively. Conclusions: Patients with single ventricles who required AVVr, particularly before bidirectional cavopulmonary shunt, have poorer transplant‐free survival with no meaningful improvement over the past 2 decades. Small weight and morphologic right ventricle were strongly associated with increased mortality. Alternative treatment strategies should be considered for this high‐risk subgroup.

1 March 2021 in Artificial Organs
Verified
Journal Article
Closed access
PDF file
SKSachiko Kadowaki
Sachiko Kadowaki
YKYasuhiro Kotani
Yasuhiro Kotani
YKYasuyuki Kobayashi
Yasuyuki Kobayashi
TGTakuya Goto
Takuya Goto
SKShingo Kasahara
Shingo Kasahara

29 January 2025 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Closed access
SKSachiko Kadowaki
Sachiko Kadowaki
CFChun-Po Steve Fan
Chun-Po Steve Fan
YZYasmin Zahiri
Yasmin Zahiri
KYKok Hooi Yap
Kok Hooi Yap
TTTeerapong Tocharoenchok
Teerapong Tocharoenchok
DBDavid J Barron
David J Barron
OBJECTIVES: This study aimed to assess the outcomes of heterotaxy patients who underwent the Fontan operation, focusing on morphological features and surgical techniques. METHODS: Eighty-two consecutive heterotaxy patients who underwent the Fontan operation from 1985 to 2021 were compared to 150 patients with tricuspid atresia (TA) and 144 patients with hypoplastic left heart syndrome (HLHS). The Kaplan–Meier method and Cox proportional hazard model were used to analyse transplant-free survival and predictor of outcomes. RESULTS: The 20-year transplant-free survival rates were comparable between right atrial isomerism (RAI, n = 45) and left atrial isomerism (LAI, n = 37) [RAI versus LAI, 76% (95% confidence interval, 57–87%) vs 68% (47–82%), P = 0.22], although more pulmonary vein interventions at Fontan were needed in RAI. Surgical techniques included extracardiac conduit in 66%, intra-atrial conduit in 9% and lateral tunnel in 18% of the cases. Cardiac position and apicocaval juxtaposition did not influence outcomes, but the inferior vena cava (IVC)-contralateral pulmonary artery (PA) Fontan was associated with 100% survival, while the IVC-ipsilateral PA Fontan at the cardiac apex showed a 67% (34–87%) survival rate at 20 years. In-hospital mortality was higher in heterotaxy [9.8% (5–19%)] compared to TA [1.3% (0.3–5.3%), P<0.01) and HLHS [2.8% (1.1–7.3%), P = 0.02], with no early death after 2000 in any group. The 20-year transplant-free survival in heterotaxy [72% (59–82%)] was similar to that in HLHS [80% (69–87%), P = 0.11]. CONCLUSIONS: Various routing techniques can be successfully applied to overcome anatomical challenges in heterotaxy. Despite higher in-hospital mortality, overall survival was similar to HLHS. RAI had comparable survival to LAI with more pulmonary vein interventions at Fontan.

17 March 2026 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
SKSachiko Kadowaki
Sachiko Kadowaki
CFChun-Po Steve Fan
Chun-Po Steve Fan
MVMaelys Venet
Maelys Venet
TTTeerapong Tocharoenchok
Teerapong Tocharoenchok
KYKok Hooi Yap
Kok Hooi Yap
OHOsami Honjo
Osami Honjo